|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:isavuconazole
|
|
gptkbp:ATCCode
|
J02AC11
|
|
gptkbp:CASNumber
|
946075-13-4
|
|
gptkbp:contraindication
|
concomitant use with strong CYP3A4 inducers
concomitant use with strong CYP3A4 inhibitors
hypersensitivity to isavuconazole
|
|
gptkbp:drugClass
|
triazole antifungal
|
|
gptkbp:EMA_approval_date
|
2015
|
|
gptkbp:FDAApproved
|
2015
|
|
gptkbp:form
|
capsule
powder for concentrate for solution for infusion
|
|
gptkbp:genericName
|
isavuconazonium sulfate
|
|
gptkbp:halfLife
|
130 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cresemba
|
|
gptkbp:indication
|
gptkb:invasive_aspergillosis
invasive mucormycosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Astellas_Pharma
|
|
gptkbp:mechanismOfAction
|
inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
hypokalemia
increased liver enzymes
|
|
gptkbp:bfsParent
|
gptkb:242138-07-4
|
|
gptkbp:bfsLayer
|
6
|